Agree Realty's Mycenax Biotech Partners with RIN Institute to Advance ADC Technology
- Mycenax Biotech partners with RIN Institute to enhance ADC capabilities using advanced VLK linker technology.
- The collaboration aims to improve cancer treatments and solidify Mycenax's position in the ADC market.
- Mycenax operates GMP-compliant facilities, ensuring quality in biologics manufacturing and supporting strategic partnerships.
Mycenax Biotech Partners with RIN Institute to Enhance ADC Capabilities
Mycenax Biotech Inc., a leading biologics Contract Development and Manufacturing Organization (CDMO) based in Taiwan, forges a strategic partnership with Japan's RIN Institute Inc. This collaboration, formalized through a License Agreement announced on October 31, 2025, enables Mycenax to leverage RIN's cutting-edge Val-Leu-Lys (VLK) linker technology. This technology is recognized for its superior anti-tumor efficacy and high serum stability, both crucial for the advancement of antibody-drug conjugates (ADCs). Mycenax's CEO, Pei-Jiun Chen, emphasizes that this partnership is a significant step in bolstering their ADC solutions, catering to the evolving needs of pharmaceutical partners.
The VLK linker technology offers a dual mechanism of action that not only enhances cytotoxicity within the tumor microenvironment but also improves the internalization of ADCs. This dual approach is critical in developing effective treatment options for cancer patients, positioning Mycenax as a frontrunner in the competitive ADC landscape. The agreement builds upon a Letter of Intent established earlier this year, signaling a long-term commitment to advancing ADC innovations. The collaboration aligns with Mycenax's strategy to provide integrated biologics solutions, further solidifying its reputation as a trusted partner in the pharmaceutical industry.
Mycenax operates two GMP-compliant facilities recognized by key regulatory authorities, including the EMA and PMDA, showcasing its commitment to quality and compliance in biologics manufacturing. In addition to its partnership with RIN Institute, Mycenax collaborates with KriSan Biotech and Spera Pharma to enhance its ADC capabilities. The company is also involved in various initiatives under Japan's MHLW subsidy program aimed at advancing biosimilar manufacturing. As the global ADC market continues to expand, Mycenax’s strategic partnerships position the company favorably to meet the increasing demand for innovative cancer therapies.
In related developments, RIN Institute's ongoing research efforts focus on advancing its lead pipeline, a humanized anti-TMEM180 antibody that is currently undergoing Phase 1 trials. This focus on innovative anti-cancer antibody drugs complements Mycenax’s objectives and enhances the overall potential of their partnership. With the ADC market evolving rapidly, this collaboration is anticipated to yield significant advancements in treatment options for oncology patients worldwide.
Related Cashu News

Lamar Advertising Co Moves to Value Indices Amid Shift in Investment Strategies
Lamar Advertising Co (Ticker: LAMR) has recently undergone a significant change in its market classification by being added to several Russell value and defensive indices. This inclusion reflects a sh…

Alexandria Real Estate Equities Advances Corporate Responsibility and Strengthens Its Position in Life Sciences
Alexandria Real Estate Equities (ARE) has made significant strides in enhancing its corporate responsibility efforts, as detailed in its recently published 2025 Corporate Responsibility Report. The re…

Healthpeak OP LLC Achieves Key Index Inclusion, Boosting Investor Interest and Trading Activity
Healthpeak OP LLC (Ticker: DOC) leverages significant market developments to reinforce its position in the real estate investment trust sector through strategic index inclusion, which may reshape inve…

Public Storage Boosts Financial Flexibility with New Credit Facility and Commercial Paper Program
Public Storage (Ticker: PSA) enhances its financial flexibility with a new unsecured credit facility and commercial paper program. Strategic Financial Innovations The company announces the closure of…

